Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Shareholders held by Collegium Pharmaceutical, Inc. on May 14, 2026. The record date for the meeting was March 31, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 32,406,969 shares were entitled to vote, with 29,210,926 shares present in person or by proxy. The following matters were approved:
- Proposal 1 (Election of Directors): All eight nominees were elected to serve until the 2027 Annual Meeting. Notable "Against" votes included 1,343,456 for Rita Balice-Gordon and 710,809 for Carlos Paya, M.D., Ph.D.
- Proposal 2 (Executive Compensation): Shareholders approved the compensation of named executive officers on an advisory basis with 26,313,792 votes "For" and 1,100,723 votes "Against."
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,953,181 votes "For" and 252,815 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific reasons for the significant "Against" votes cast for directors Rita Balice-Gordon and Carlos Paya.
- Confirm the total number of shares outstanding and the percentage of ownership represented by the 1,790,765 broker non-votes.
- Review the full proxy statement for details on executive compensation packages approved under Proposal 2.